International Psoriasis Council is located in St Charles, MO. The organization was established in 2005. According to its NTEE Classification (H40) the organization is classified as: Diseases of Specific Organs Research, under the broad grouping of Medical Research and related organizations. As of 12/2021, International Psoriasis Council employed 5 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. International Psoriasis Council is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, International Psoriasis Council generated $1.6m in total revenue. The organization has seen a slow decline revenue. Over the past 7 years, revenues have fallen by an average of (0.1%) each year. All expenses for the organization totaled $964.5k during the year ending 12/2021. As we would expect to see with falling revenues, expenses have declined by (6.6%) per year over the past 7 years. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
ADVANCING PSORIASIS RESEARCH AND TREATMENT THROUGH EDUCATION, COLLABORATION, AND INNOVATION
Describe the Organization's Program Activity:
Part 3 - Line 4a
EDUCATION - TO ENHANCE THE CARE OF PATIENTS WORLDWIDE, IPC DELIVERS A VARIETY OF EDUCATIONAL PROGRAMS FOR HEALTH CARE PROFESSIONALS AROUND THE WORLD. IN RESPONSE TO THE CANCELLATION OF MANY IN-PERSON CONGRESSES, IPC PARTICIPATED IN THESE CONFERENCES VIRTUALLY. IN ADDITION, A GLOBAL WEBINAR SERIES WAS DELIVERED, AND IPC FELLOWS PARTICIPATED IN ONLINE ACTIVITIES. IPC EXPERTS SPOKE ABOUT VARIOUS TOPICS, INCLUDING COVID-19 AND PSORIASIS; IPC'S DISEASE SEVERITY RECLASSIFICATION PROJECT AND ITS IMPLICATION IN CLINICS; THE FUTURE OF TELEDERMATOLOGY; DISEASE MODELS FOR BIOMARKER RESEARCH; PSORIASIS AND PSORIATIC ARTHRITIS BIOMARKERS; AND MACHINE LEARNING APPROACHES FOR PSORIASIS RESEARCH; AMONG OTHERS. IPC ALSO PRODUCED ON-LINE CONTENT IN THE FORM OF VIDEOS, EXPERT COMMENTARIES AND...(CONTINUED ON SCH O)(EDUCATION CONTINUED) CONGRESS REPORTS. THROUGH THESE ACTIVITIES, MORE THAN 30,000 PROFESSIONALS WERE PROVIDED WITH DISEASE INFORMATION, MEDICAL EDUCATION, AND CLINICAL RESOURCES.
RESEARCH - COVID-19: THE IPC BOARD OF DIRECTORS HAS CONTINUED TO MONITOR THE PANDEMIC'S EFFECT ON PSORIASIS CARE. THE WEB-BASED COVID-19 RESOURCE CENTER HAS RECEIVED OVER 3,200 VISITS. THE RESOURCE CENTER INCLUDES VIDEOS FEATURING REAL-WORLD EXPERIENCES FROM PHYSICIANS AT THE FOREFRONT OF THE PANDEMIC, EXPERT OPINIONS ON PUBLISHED MANUSCRIPTS, LINKS TO TREATMENT GUIDELINES, AND INFORMATION ON THE PSOPROTECT AND PSOPROTECTME COVID-19 REGISTRIES. IPC IS A GLOBAL PARTNER OF THE PSOPROTECT AND PSOPROTECTME COVID-19 REGISTRIES. WE HAVE ENCOURAGED THE IPC COMMUNITY TO REPORT OUTCOMES OF COVID-19 IN INDIVIDUALS WITH PSORIASIS. THE REGISTRY NOW INCLUDES 1,272 PARTICIPANTS. ADDITIONALLY, SIX COMMENTARIES ON KEY MANUSCRIPTS HAVE BEEN POSTED TO OUR WEBSITE AND HAVE RECEIVED A COMBINED TOTAL OF 2,200 VIEWS...(CONTINUED ON SCH O)(RESEARCH CONTINUED) IPC ISSUED A SURVEY TO THE COUNCILORS TO RECEIVE RECOMMENDATIONS FOR ACTIVITIES IN THE FUTURE YEARS. PUSTULAR PSORIASIS: IPC'S PUSTULAR PSORIASIS PROJECT AIMS TO IMPROVE THE UNDERSTANDING OF THIS RARE AND LIFE-THREATENING DISEASE AND WILL INCLUDE ACTIVITIES TO IMPROVE PATIENT CARE. THE RECENTLY FORMED WORKING GROUP IS CURRENTLY DEVELOPING PRELIMINARY PLANS FOR 2022, WHICH MAY INCLUDE: DEFINING THE OBJECTIVES AND ADDRESSING THE FEASIBILITY OF REAL-WORLD DATA COLLECTION THROUGH INTERNATIONAL COLLABORATION WITH PUSTULAR PSORIASIS CLINICAL CENTERS AND LABORATORIES; REACHING A GLOBAL CONSENSUS ON PUSTULAR PSORIASIS SCORING ASSESSMENTS; INITIATING INTRA-RATER AND INTER-RATER VARIABILITY VALIDATION STUDIES; DEVELOPING TRAINING MODULES ON PUSTULAR SCORES AND CERTIFICATION FOR CLINICAL TRIAL INVESTIGATORS; AND HOSTING AN EXPERT ROUNDTABLE/MEETING ON PUSTULAR PSORIASIS IN ASIA.
ACCESS TO CARE - RECLASSIFICATION OF DISEASE SEVERITY: IN 2019, IPC PUBLISHED A CONSENSUS STATEMENT THAT REJECTED THE TRADITIONAL CLASSIFICATIONS OF PSORIASIS AS MILD, MODERATE, AND SEVERE AND INSTEAD RECOMMENDED THAT PSORIASIS PATIENTS BE CLASSIFIED AS EITHER A CANDIDATE FOR TOPICAL THERAPY OR A CANDIDATE FOR SYSTEMIC THERAPY. OVER THE PAST YEAR, IPC HAS EDUCATED OVER 5,000 DERMATOLOGISTS, THROUGH MASTERCLASSES, CONGRESS SYMPOSIA, AND OUR TAKE TEN VIDEO PROJECT, ON THE VALUE OF USING THE NEW CATEGORIZATION IN THEIR DAILY PRACTICE TO INCREASE THE NUMBER OF PATIENTS RECEIVING THE APPROPRIATE TREATMENT. IN ADDITION, IPC WORKED WITH NATIONAL ENTITIES TO SECURE INCLUSION OF THE CLASSIFICATION IN THE UPDATE OF TWO EUROPEAN TREATMENT GUIDELINES AND PARTNERED WITH THE NPF TO ANALYZE THEIR ANNUAL...(CONTINUED ON SCH O)(ACCESS TO CARE CONTINUED) PATIENT SURVEY DATE. THE ANALYSIS IS COMPLETE, AND A MANUSCRIPT IS CURRENTLY IN DEVELOPMENT. TELEMEDICINE: IPC CONVENED A WORKING GROUP TO ESTABLISH A ROAD MAP FOR HOW IPC CAN AID THE DEVELOPMENT AND IMPLEMENTATION OF TELEMEDICINE FOCUSED ON PSORIASIS DIAGNOSIS AND MANAGEMENT. THE TELEMEDICINE WORKING GROUP, CHAIRED BY ALEXANDER NAVARRINI AND CO-CHAIRED BY JOEL GELFAND, IS DEVELOPING CONSENSUS STATEMENTS REGARDING TELEMEDICINE IN PSORIASIS MANAGEMENT. FOLLOWING THE PUBLISHING OF THE STATEMENTS, THE WORKING GROUP WILL CONTINUE TO WORK TOWARD OTHER ACTIONS. A CONSENSUS MANUSCRIPT, INCLUDING 34 STATEMENTS IS IN DEVELOPMENT AND WILL BE PUBLISHED NEXT YEAR.GLOBAL PSORIASIS ATLAS: PHASE TWO OF THE GLOBAL PSORIASIS ATLAS (GPA) PROJECT HAS BEEN INITIATED IN PARTNERSHIP WITH THE ILDS (INTERNATIONAL LEAGUE OF DERMATOLOGICAL SOCIETIES) AND IFPA (INTERNATIONAL FEDERATION OF PSORIASIS ASSOCIATIONS). THE UNIVERSITY OF MANCHESTER WILL CONTINUE TO SERVE AS THE LEAD ACADEMIC INSTITUTION FOR THE PROJECT. WORKSTREAMS FOR PHASE TWO INCLUDE: - EPIDEMIOLOGY OF PSORIASIS, - EARLY DIAGNOSIS OF PSORIASIS, - COMORBID DISEASE BURDEN OF PSORIASIS, AND - THE ECONOMIC IMPACT OF PSORIASIS.OVER THE PAST YEAR, FIVE MANUSCRIPTS WERE PUBLISHED ON TOPICS INCLUDING CANCER, PSORIASIS PREVALENCE IN THE UNITED STATES, THE INCIDENCE OF PSORIASIS IN CHILE, AND THE DEVELOPMENT OF CLINICAL DIAGNOSTIC CRITERIA FOR PLAQUE PSORIASIS. STUDIES COMPLETED IN TAIWAN AND MALAYSIA HAVE PUBLICATIONS PENDING SUBMISSION OR ACCEPTANCE. NEW STUDIES ARE ALSO UNDERWAY IN GREENLAND, NEW FOUNDLAND, AND QATAR.
OUTREACH AND OTHER PROGRAMS - IPC PARTICIPATED VIRTUALLY IN SEVERAL CONGRESSES TO GROW ITS REACH AND INFLUENCE THROUGHOUT THE WORLD. CONGRESSES INCLUDED THE SOCIETY OF INVESTIGATIVE DERMATOLOGY, THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, THE 6TH WORLD PSORIASIS & PSORIATIC ARTHRITIS CONFERENCE, THE EUROPEAN SOCIETY OF DERMATOLOGICAL RESEARCH, AND THE REUNION ANUAL DE DERMATOLOGOS LATINOAMERICANOS. EACH CONGRESS IS CHARGED WITH EDUCATING DERMATOLOGISTS AND SHARING BEST PRACTICES FOR IMPROVED CLINICAL CARE.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Christy Langan Chief Executive Officer | Officer | 40 | $231,967 |
Craig Leonardi Vice Pres./president-Elect | OfficerTrustee | 1 | $0 |
Bruce Strober Secretary/treasurer | OfficerTrustee | 1 | $0 |
Jonathan Barker President | OfficerTrustee | 2 | $0 |
Herve Bachelez Director | Trustee | 0.5 | $0 |
Mahira El Sayed Director | Trustee | 0.5 | $0 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Tina A Burke Consulting Corporate Relations And Events | 12/30/21 | $110,000 |
Dermatologie Uitgeest Bv Medical Director Fees | 12/30/21 | $101,764 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $56,511 |
All other contributions, gifts, grants, and similar amounts not included above | $1,562,703 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $1,619,214 |
Total Program Service Revenue | $0 |
Investment income | $3,315 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $0 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $1,622,529 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $0 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $12,432 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $239,637 |
Compensation of current officers, directors, key employees. | $46,505 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $201,738 |
Pension plan accruals and contributions | $6,030 |
Other employee benefits | $7,392 |
Payroll taxes | $28,598 |
Fees for services: Management | $0 |
Fees for services: Legal | $9,375 |
Fees for services: Accounting | $47,317 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $313,675 |
Advertising and promotion | $8,674 |
Office expenses | $24,422 |
Information technology | $36,648 |
Royalties | $0 |
Occupancy | $0 |
Travel | $11,953 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $13,761 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $0 |
Insurance | $2,885 |
All other expenses | $0 |
Total functional expenses | $964,537 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $2 |
Savings and temporary cash investments | $3,422,072 |
Pledges and grants receivable | $10,000 |
Accounts receivable, net | $0 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $10,668 |
Net Land, buildings, and equipment | $0 |
Investments—publicly traded securities | $0 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $40,327 |
Other assets | $0 |
Total assets | $3,483,069 |
Accounts payable and accrued expenses | $29,294 |
Grants payable | $0 |
Deferred revenue | $375,000 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $0 |
Total liabilities | $404,294 |
Net assets without donor restrictions | $3,078,775 |
Net assets with donor restrictions | $0 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $3,483,069 |
Organization Name | Assets | Revenue |
---|---|---|
National Stem Cell Foundation Inc Louisville, KY | $8,111,646 | $1,286,461 |
International Psoriasis Council St Charles, MO | $3,483,069 | $1,622,529 |
Healthcare 21 Business Coalition Knoxville, TN | $1,495,482 | $550,608 |
Scleroderma Foundation Of Greater Chicago Chicago, IL | $3,677,722 | $389,268 |
North American Hair Research Society Chicago, IL | $532,701 | $140,705 |
Prostate Cancer Foundation Of Chicago Westmont, IL | $376,776 | $0 |
Community Mercantile Educational Foundation Inc Lawrence, KS | $87,385 | $0 |
The Difference Principle Foundation Tulsa, OK | $83,598 | $2,326 |